NEW YORK (Reuters) - An experimental Merck & Co. vaccine completely prevented early-stage cervical cancer and precancerous cervical lesions caused by the two most common forms of a virus linked to such cancers, Merck said on Thursday.
"This trial confirms that a vaccine can give young women a high level of protection from developing precancerous lesions and early cervical cancers," Laura Koutsky, a professor of epidemiology at the University of Washington who led the study, told Reuters.